4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
3D Medicines Inc. (1244) operates in the Biotechnology industry and is headquartered in Qingdao, China with about 162 employees. Its market capitalization is roughly HK$690 million. In the fiscal year ended 2025-12-31, 1244 reported CNY 356M in revenue and (CNY 178M) in net income.
3D Medicines Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People's Republic of China.
Interactive charts & full statements → Open the 1244 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 356M | CNY 446M | CNY 635M | CNY 567M | — |
| Gross Profit | CNY 328M | CNY 409M | CNY 586M | CNY 525M | — |
| Operating Income (EBIT) | (CNY 74M) | (CNY 79M) | (CNY 421M) | (CNY 321M) | — |
| Net Income | (CNY 178M) | (CNY 183M) | (CNY 525M) | (CNY 1.0B) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 936M | CNY 1.2B | CNY 1.4B | CNY 1.3B | — |
| Total Liabilities | CNY 391M | CNY 512M | CNY 558M | CNY 437M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1244 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms